- Investor's Business Daily•12 hours ago
The FDA's approval rate fell to a nine-year low in 2016 despite additions from Biogen, Merck and Eli Lilly.
- Investopedia•17 hours ago
The collaboration aims to develop MRI tools to treat multiple sclerosis.
- Zacks•20 hours ago
Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will be reporting fourth-quarter 2016 and full-year earnings on Jan 26.
BIIB : Summary for Biogen Inc. - Yahoo Finance
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||279.64 x 100|
|Ask||284.58 x 100|
|Day's Range||279.23 - 284.84|
|52 Week Range||223.02 - 333.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||15.86|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|